Overall, event-free, relapse-free survival improved in patients receiving higher doses of tisagenlecleucel, with no increased toxicity
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
TUESDAY, Aug. 9, 2022 (HealthDay News) -- For pediatric patients with B-cell acute lymphoblastic leukemia, higher doses of tisagenlecleucel, the chimeric antigen receptor T (CAR T)-cell therapy targeting CD19, are associated with improved survival, according to a study published online Aug. 8 in Blood Advances.
Heather E. Stefanski, M.D., Ph.D., from the National Marrow Donor Program and the University of Minnesota Medical School in Minneapolis, and colleagues examined whether CAR T-cell dose impacts overall survival, event-free survival, and relapse-free survival in recipients of tisagenlecleucel using data from 185 pediatric patients infused with commercial tisagenlecleucel. To examine the impact of cell dose, responders were categorized into dose quartiles.
The researchers found that patients who received higher doses of tisagenlecleucel had improved overall survival, event-free survival, and relapse-free survival. There was no association observed for higher doses of tisagenlecleucel with increased toxicity.
"In the past, we did not have data to guide clinical decisions around commercial CAR T-cell dosing and didn't know if higher doses would affect toxicity and compromise outcomes, or support enhanced antileukemia effect," a coauthor said in a statement. "This data has direct clinical applicability, as it supports use of higher dosing, as available, within the approved tisagenlecleucel dose range."
Several authors disclosed financial ties to pharmaceutical companies, including Novartis, the manufacturer of tisagenlecleucel.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Updated on September 21, 2022
Read this Next
Other Trending Articles